risperidone (Q412443)

reactant

1 reference

Gene Ontology release 2019-11-16

has use

medication

0 references

chemical structure

Risperidone Structural Formulae V.1.svg
804 × 339; 17 KB

criterion used

structure representation with labelled terminal carbon atoms

0 references

Risperidone.svg
512 × 224; 5 KB

criterion used

structure representation with unlabelled terminal carbon atoms

0 references

mass

410.211804 dalton

1 reference

risperidone (English)

3 October 2016

chemical formula

C₂₃H₂₇FN₄O₂

1 reference

risperidone (English)

19 November 2016

canonical SMILES

CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F

1 reference

risperidone (English)

19 November 2016

defined daily dose

5 milligram

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05AX08

2.7 milligram

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05AX08

1 reference

14 February 2018

World Health Organisation international non-proprietary name

risperidone (English)

1 reference

risperidone (English)

medical condition treated

3 October 2016

1 reference

13 December 2016

1 reference

13 December 2016

1 reference

13 December 2016

2 references

13 December 2016

pervasive developmental disorder

2 October 2018

1 reference

13 December 2016

2 references

13 December 2016

2 October 2018

conduct disorder

1 reference

2 October 2018

personality disorder

1 reference

2 October 2018

Alzheimer's disease

1 reference

oppositional defiant disorder

2 October 2018

1 reference

2 October 2018

mental disorder

1 reference

2 October 2018

mood disorder

1 reference

2 October 2018

psychosis

1 reference

2 October 2018

insomnia

1 reference

2 October 2018

intellectual disability

1 reference

obsessive-compulsive disorder

2 October 2018

1 reference

post-traumatic stress disorder

2 October 2018

1 reference

intermittent explosive disorder

2 October 2018

1 reference

2 October 2018

anxiety

1 reference

2 October 2018

impulse control disorder

1 reference

2 October 2018

schizoaffective disorder

1 reference

2 October 2018

anxiety disorder

1 reference

2 October 2018

sleep-wake disorder

1 reference

2 October 2018

29 December 1993

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/L6UH7ZF8HC

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01859e07-1262-4cc6-b7ed-5a273cbf0c36

schizophrenia

start time

29 December 1993

approved by

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/L6UH7ZF8HC

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01859e07-1262-4cc6-b7ed-5a273cbf0c36

autism

start time

29 December 1993

approved by

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/L6UH7ZF8HC

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01859e07-1262-4cc6-b7ed-5a273cbf0c36

significant drug interaction

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tetrabenazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ropinirol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bromocriptine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levodopa

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

buprenorphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

extrapyramidal symptoms

1 reference

A reference set of clinically relevant adverse drug-drug interactions

encephalopathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dyskinesia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

asthenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

brain injury

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonidine

orthostatic intolerance

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 1A

1 reference

5-hydroxytryptamine receptor 1B

17 August 2016

1 reference

5-hydroxytryptamine receptor 1D

17 August 2016

1 reference

5-hydroxytryptamine receptor 1E

17 August 2016

1 reference

5-hydroxytryptamine receptor 1F

17 August 2016

1 reference

5-hydroxytryptamine receptor 2A

17 August 2016

1 reference

5-hydroxytryptamine receptor 2C

17 August 2016

1 reference

5-hydroxytryptamine receptor 6

17 August 2016

1 reference

5-hydroxytryptamine receptor 7

17 August 2016

1 reference

17 August 2016

Adrenoceptor alpha 1A

1 reference

17 August 2016

Adrenoceptor alpha 1B

1 reference

17 August 2016

Adrenoceptor alpha 1D

1 reference

17 August 2016

1 reference

17 August 2016

1 reference

17 August 2016

Histamine receptor H1

1 reference

17 August 2016

legal status (medicine)

boxed warning

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category B3

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Risperidone

4 June 2018

1 reference

5 March 2018

2 references

5 March 2018

Medical Subject Headings

15 March 2018

2 references

5 March 2018

Medical Subject Headings

15 March 2018

1 reference

5 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

D018967

15 March 2018

atypical antipsychotic

0 references

0 references

risperiDONE

subject named as

Risperidone

1 reference

https://www.fda.gov/drugs/medication-errors-related-cder-regulated-drug-products/fda-name-differentiation-project

Institute for Safe Medication Practices

2 September 2022

RisperDAL

has characteristic

Tall Man lettering

issued by

subject named as

Risperdal

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

0 references

Risperidone

0 references

Identifiers

InChI

InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

1 reference

risperidone (English)

19 November 2016

2 references

risperidone (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

106266-06-2

2 references

risperidone (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=106266-06-2

8 April 2021

1 reference

Risperidone (English)

19 November 2016

2 references

risperidone (English)

19 November 2016

Reaxys registry number

4891881

1 reference

risperidone (English)

3 October 2016

ChEBI ID

8871

mapping relation type

2 references

RISPERIDONE (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

1 reference

RISPERIDONE (English)

19 November 2016

2 references

inferred from InChIKey

MSBNK-Athens_Univ-AU150501

1 reference

MassBank accession ID

SM851301

0 references

0 references

MSBNK-Athens_Univ-AU150502

0 references

MSBNK-Athens_Univ-AU150503

0 references

MSBNK-Athens_Univ-AU150504

0 references

MSBNK-Athens_Univ-AU150505

0 references

MSBNK-Athens_Univ-AU150507

0 references

MSBNK-Athens_Univ-AU150508

0 references

MSBNK-Athens_Univ-AU150509

0 references

MSBNK-Athens_Univ-AU150510

0 references

MSBNK-Athens_Univ-AU150511

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

MSBNK-Waters-WA000534

0 references

MSBNK-Waters-WA000535

0 references

MSBNK-Waters-WA000536

0 references

MSBNK-Waters-WA000537

0 references

MSBNK-Waters-WA000538

0 references

SPLASH

splash10-03dl-0800900000-4e0f5ed855c5bb92c98f

0 references

splash10-01ox-0900600000-8473cdb789508bd753a4

0 references

splash10-0006-0900000000-3d06f3ad1210b9482139

0 references

splash10-0006-0900000000-d0dcf9d7f61a2c2bc652

0 references

splash10-03di-0000900000-dde599ea867efca2809b

0 references

splash10-0006-0900300000-9a423e6e6775ee918924

0 references

splash10-0006-0900000000-b3a1059a8514321aac84

0 references

splash10-0006-0900000000-3160d58bf1d154a8d21c

0 references

splash10-0006-2900000000-530259828e362c7f2a3c

0 references

splash10-02u3-8900000000-c5ae8612478a7ea315c0

0 references

splash10-066r-9200000000-466435c830554a2d51ea

0 references

splash10-066r-9100000000-352e00f2fbc78e81df2c

0 references

splash10-066r-9000000000-de0b42c9894812c69015

0 references

splash10-03dl-1901800000-c9a45676bc3a1d1829b7

0 references

splash10-0a4i-2980000000-3574e0025348c64db6fc

0 references

splash10-0006-0900300000-2ca53f2d737c37046831

0 references

HSDB ID

7580

1 reference

Hazardous Substances Data Bank

28 October 2019

RISPERIDONE (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.705

27 December 2018

ECHA Substance Infocard ID

3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one (English)

quotation

CAS no.: 106266-06-2 (English)

100.114.705

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.114.705

27 December 2018

3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one (English)

quotation

CAS no.: 106266-06-2 (English)

1 reference

Risperidone (English)

publication date

17 November 2015

1 reference

risperidone (English)

19 November 2016

Risperidone

0 references

0 references

0 references

1 reference

risperidone (English)

19 November 2016

DrugBank ID

DB00734

1 reference

Human Metabolome Database ID

HMDB0005020

2 references

based on heuristic

inferred from InChIKey

2 references

risperidone (English)

19 November 2016

MedlinePlus drug identifier

a694015

oral administration

0 references

a615012

PatientsLikeMe treatment ID

injection

0 references

0 references

1 reference

risperidone (English)

19 November 2016

0 references

1 reference

1 reference

electronic Essential Medicines List medicine ID

risperidone (English)

3 October 2016

0 references

0 references

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

UK Parliament thesaurus ID

501195

subject named as

Risperidone

0 references

UMLS CUI

C0073393

1 reference